Summit Therapeutics annual ebitda
2018
2019
2020
2021
2022
2023
2024
2025
Summit Therapeutics EBITDA Growth & History (SMMT)
Summit Therapeutics's calculated EBITDA was −$1.08B for fiscal 2025.
View full Summit Therapeutics company overviewSummit Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$1.08B | −$853.5M | — |
| 2024 | 2024-12-31 | −$225.9M | $383.5M | — |
| 2023 | 2023-12-31 | −$609.5M | −$538.6M | — |
| 2022 | 2022-12-31 | −$70.8M | $14.0M | — |
| 2021 | 2021-12-31 | −$84.8M | −$33.2M | — |
| 2020 | 2020-12-31 | −$51.6M | −$25.5M | — |
| 2019 | 2019-12-31 | −$26.2M | — | — |
| 2018 | 2019-01-31 | $6.9M | — | — |
Summit Therapeutics quarterly ebitda
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$220.4M | $347.9M | — |
| Q1 2026 | 2026-03-31 | −$195.2M | — | — |
| Q4 2025 | 2025-12-31 | −$219.1M | −$153.5M | — |
| Q3 2025 | 2025-09-30 | −$231.8M | −$173.4M | — |
| Q2 2025 | 2025-06-30 | −$568.4M | −$508.8M | — |
| Q4 2024 | 2024-12-31 | −$65.6M | −$29.4M | — |
| Q3 2024 | 2024-09-30 | −$58.4M | −$37.9M | — |
| Q2 2024 | 2024-06-30 | −$59.6M | −$43.8M | — |
| Q1 2024 | 2024-03-31 | −$42.4M | $494.7M | — |
| Q4 2023 | 2023-12-31 | −$36.2M | −$16.2M | — |
| Q3 2023 | 2023-09-30 | −$20.5M | −$3.8M | — |
| Q2 2023 | 2023-06-30 | −$15.7M | −$3.4M | — |
| Q1 2023 | 2023-03-31 | −$537.1M | −$515.2M | — |
| Q4 2022 | 2022-12-31 | −$20.0M | $5.7M | — |
| Q3 2022 | 2022-09-30 | −$16.6M | $2.5M | — |
| Q2 2022 | 2022-06-30 | −$12.4M | $11.0M | — |
| Q1 2022 | 2022-03-31 | −$21.8M | −$5.3M | — |
| Q4 2021 | 2021-12-31 | −$25.7M | −$14.6M | — |
| Q3 2021 | 2021-09-30 | −$19.1M | −$2.6M | — |
| Q2 2021 | 2021-06-30 | −$23.4M | −$8.4M | — |
| Q1 2021 | 2021-03-31 | −$16.6M | −$7.6M | — |
| Q4 2020 | 2020-12-31 | −$11.1M | — | — |
| Q3 2020 | 2020-09-30 | −$16.5M | — | — |
| Q2 2020 | 2020-06-30 | −$15.0M | — | — |
| Q1 2020 | 2020-03-31 | −$9.0M | — | — |
Summit Therapeutics ebitda trends
Over the last five fiscal years, Summit Therapeutics's ebitda decreased from −$51.6M to −$1.08B, a change of −$1.03B. The latest reported quarter, Q2 2026, shows −$220.4M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Summit Therapeutics source filings ↗Community posts
AstraZeneca commits $2 billion to Summit alongside cancer-trial collaboration
AstraZeneca ($AZN) has agreed to invest $2 billion in Summit Therapeutics ($SMMT) through preferred shares convertible into common stock at an effective $18.36 per share. Approximately 108,955 preferred shares would each convert into 1,000 ...
